Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free POLB Stock Alerts

Poolbeg Pharma (POLB) Competitors

Poolbeg Pharma logo
GBX 9.07 +0.38 (+4.31%)
As of 12:24 PM Eastern
Compare

POLB vs. ARIX, CIR, TILS, VSN, and SCLP

Should you buy Poolbeg Pharma stock or one of its competitors? Poolbeg Pharma's main competitors and comparable companies include Arix Bioscience (ARIX), Circassia Group (CIR), Tiziana Life Sciences (TILS), Verseon (VSN), and Scancell (SCLP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Poolbeg Pharma compare to Arix Bioscience?

Poolbeg Pharma (LON:POLB) and Arix Bioscience (LON:ARIX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Arix Bioscience has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A
Arix Bioscience£14.16M0.00£14.96M£0.11N/A

Arix Bioscience has a net margin of 105.64% compared to Poolbeg Pharma's net margin of 0.00%. Arix Bioscience's return on equity of 6.41% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Poolbeg PharmaN/A -55.47% -21.33%
Arix Bioscience 105.64%6.41%2.18%

5.1% of Poolbeg Pharma shares are held by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are held by institutional investors. 7.5% of Poolbeg Pharma shares are held by insiders. Comparatively, 20.7% of Arix Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Poolbeg Pharma has a beta of 1.828, indicating that its share price is 83% more volatile than the broader market. Comparatively, Arix Bioscience has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

In the previous week, Poolbeg Pharma's average media sentiment score of 0.00 equaled Arix Bioscience'saverage media sentiment score.

Company Overall Sentiment
Poolbeg Pharma Neutral
Arix Bioscience Neutral

Summary

Arix Bioscience beats Poolbeg Pharma on 9 of the 10 factors compared between the two stocks.

How does Poolbeg Pharma compare to Circassia Group?

Poolbeg Pharma (LON:POLB) and Circassia Group (LON:CIR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

5.1% of Poolbeg Pharma shares are held by institutional investors. 7.5% of Poolbeg Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Poolbeg Pharma's average media sentiment score of 0.00 equaled Circassia Group'saverage media sentiment score.

Company Overall Sentiment
Poolbeg Pharma Neutral
Circassia Group Neutral

Circassia Group has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A
Circassia Group£27.90M0.00N/A£0.01N/A

Circassia Group's return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Poolbeg PharmaN/A -55.47% -21.33%
Circassia Group N/A N/A N/A

Summary

Circassia Group beats Poolbeg Pharma on 5 of the 7 factors compared between the two stocks.

How does Poolbeg Pharma compare to Tiziana Life Sciences?

Tiziana Life Sciences (LON:TILS) and Poolbeg Pharma (LON:POLB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Tiziana Life Sciences has higher earnings, but lower revenue than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A

In the previous week, Tiziana Life Sciences had 4 more articles in the media than Poolbeg Pharma. MarketBeat recorded 4 mentions for Tiziana Life Sciences and 0 mentions for Poolbeg Pharma. Tiziana Life Sciences' average media sentiment score of 1.18 beat Poolbeg Pharma's score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Tiziana Life Sciences Positive
Poolbeg Pharma Neutral

5.1% of Poolbeg Pharma shares are held by institutional investors. 7.5% of Poolbeg Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Tiziana Life Sciences' return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Tiziana Life SciencesN/A N/A N/A
Poolbeg Pharma N/A -55.47%-21.33%

Summary

Tiziana Life Sciences beats Poolbeg Pharma on 5 of the 9 factors compared between the two stocks.

How does Poolbeg Pharma compare to Verseon?

Poolbeg Pharma (LON:POLB) and Verseon (LON:VSN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Poolbeg Pharma is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A
VerseonN/AN/AN/A-£14.30N/A

5.1% of Poolbeg Pharma shares are held by institutional investors. 7.5% of Poolbeg Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Poolbeg Pharma's average media sentiment score of 0.00 equaled Verseon'saverage media sentiment score.

Company Overall Sentiment
Poolbeg Pharma Neutral
Verseon Neutral

Verseon's return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Poolbeg PharmaN/A -55.47% -21.33%
Verseon N/A N/A N/A

Summary

Poolbeg Pharma and Verseon tied by winning 3 of the 6 factors compared between the two stocks.

How does Poolbeg Pharma compare to Scancell?

Scancell (LON:SCLP) and Poolbeg Pharma (LON:POLB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Poolbeg Pharma has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Scancell-116.98% 90.29% -45.28%
Poolbeg Pharma N/A -55.47%-21.33%

Scancell has a beta of 0.687, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Poolbeg Pharma has a beta of 1.828, suggesting that its share price is 83% more volatile than the broader market.

Scancell has higher revenue and earnings than Poolbeg Pharma. Scancell is trading at a lower price-to-earnings ratio than Poolbeg Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scancell£4.71M22.27-£6.75M-£0.55N/A
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A

In the previous week, Scancell had 1 more articles in the media than Poolbeg Pharma. MarketBeat recorded 1 mentions for Scancell and 0 mentions for Poolbeg Pharma. Scancell's average media sentiment score of 0.75 beat Poolbeg Pharma's score of 0.00 indicating that Scancell is being referred to more favorably in the media.

Company Overall Sentiment
Scancell Positive
Poolbeg Pharma Neutral

1.5% of Scancell shares are owned by institutional investors. Comparatively, 5.1% of Poolbeg Pharma shares are owned by institutional investors. 13.2% of Scancell shares are owned by company insiders. Comparatively, 7.5% of Poolbeg Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Scancell beats Poolbeg Pharma on 7 of the 12 factors compared between the two stocks.

Get Poolbeg Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for POLB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

POLB vs. The Competition

Export
MetricPoolbeg PharmaBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£69.28M£3.90B£7.26B£2.89B
Dividend YieldN/A3.64%2.53%6.22%
P/E Ratio-9.6514.12274.69366.69
Price / SalesN/A1,420.42647.1990,194.92
Price / Cash2.1141.6228.0427.89
Price / Book0.0015.6010.566.37
Net Income-£4.50B-£22.86M£3.49B£5.89B
7 Day Performance8.04%-1.25%-0.23%1.00%
1 Month Performance2.94%-4.56%-2.80%-0.05%
1 Year Performance130.86%38.32%18.25%19.57%

Poolbeg Pharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
POLB
Poolbeg Pharma
N/AGBX 9.08
+4.3%		N/A+121.3%£69.28MN/AN/A12
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60MN/A11
VSN
Verseon
N/AN/AN/AN/A£112.24MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:POLB) was last updated on 9/21/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel